Overview
Biosimilars provide safe and effective treatment options for a variety of conditions, and can be a more cost effective option than standard biologics. The Centers for Medicare and Medicaid Services (CMS) is responsible to establish coding, coverage, and payment policies for biosimilars and many commercial payers will either follow suit to what CMS does or will wait and see approach until we have more biosimilars on the market. This virtual session will explore recent policies focused on the reimbursement of biosimilars and the potential implications to the US market.
Featured Topics
- Payments for Biosimilars Under Medicare Part B
- Overview (J-code, Pass-through)
- Implications
- Key outstanding issues
- Payments for Biosimilars Under Medicare Part D
- Overview (Coverage Gap, cost-sharing changes)
- Implications
- Key outstanding issues
- Biosimilars to be Subject to Changes to 340B Drug Pricing
Back to the Biosimilars Virtual Conference.
Learning objectives
At the conclusion of this session, participants should be able to:
- Gain a high-level understanding of the US reimbursement landscape as it relates to biosimilars and interchangeable biological products
- Assess the impact of reimbursement policies on market uptake and sustainability of biosimilars and interchangeable biological products
The Drug Information Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Drug Information Association designates this educational activity for up to 1.5 contact hours or .15 CEUs. 0286-0000-18-063-H04-P Type of Activity: Knowledge
Drug Information Association has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET).
As an IACET Authorized Provider, Drug Information Association offers CEUs for its programs that qualify under the ANSI/IACET Standard. Drug Information Association is authorized by IACET to offer .2 CEUs for this program.
In order to request your online credit through My Transcript, visit www.diaglobal.org, select “Sign in” and you will be prompted for your user ID and password (if you do not know your username and password, choose Forgot Your User ID/Password). Find EVENTS, select “Continuing Education”. Select the blue “My Transcript” button followed by “Credit Request”.
To review DIA’s Grievance Policy, visit DIAglobal.org/CE
Program Committee
-
Leah Christl, PhD Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy
Amgen, United States -
Hillel P Cohen, PhD Executive Director, Scientific Affairs
Sandoz Inc., United States -
Thomas Felix, MD Medical Director, R&D Policy, Global Regulatory Affairs and Safety
Amgen Inc., United States -
Julie Marechal-Jamil, MSc Director, Biosimilar Policy and Science
Medicines For Europe, Belgium -
Laura McKinley, PhD Director, Global Regulatory Policy and Intelligence
Pfizer Inc, United States -
Cecil J. Nick, MS FTOPRA, Vice President (Technical)
Parexel Consulting, United Kingdom -
Jian Wang, MD, PhD Division Manager, Clinical Review Division – Heamatology/Oncology
Health Canada, Canada
Have an account?